 NEW HAVEN, Conn., June 22, 2021 GLOBE NEWSWIRE -- BioXcel Therapeutics, Inc. the Company Nasdaq: BTAI, a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an underwritten public offering of 100.0 million of shares of its common stock. In addition, a related party stockholder, BioXcel LLC, expects to grant the underwriters a 30-day option to purchase up to 15.0 million of additional shares of common stock at the public offering price, less underwriting discounts and commissions. 